Sorting bone and soft tissue tumors into groups by their genes
Studies whether gene tests can classify bone and soft tissue tumors more clearly.
Plain-language title generated from the registry record
Registry title: Molecular and Clinical Studies of Bone and Soft Tissue Tumors
Key facts
- Where
- Stockholm, SwedenSee the site
Where in Sweden
- Karolinska University HospitalStockholm, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Karolinska Institutet
- Trial code
- NCT07822204
- Record updated
- 2 October 2026
- Original description
The goal of this observational study is to learn whether tumors of bone and soft tissue can be sorted into groups by their genes. Today these tumors are named mainly by how they look under a microscope. There are more than 150 names in use. The same tumor can be given different names by different doctors.Read full original descriptionShow less
Molekylära Och Kliniska Studier av Ben- Och mjukdelstumörer
The goal of this observational study is to learn whether tumors of bone and soft tissue can be sorted into groups by their genes. Today these tumors are named mainly by how they look under a microscope. There are more than 150 names in use. The same tumor can be given different names by different doctors.
The study includes people of any age with a bone or soft tissue tumor. All of them had tissue sampled at Karolinska University Hospital in Stockholm, Sweden.
The main questions it aims to answer are:
Can tests of a tumor's genes sort these tumors into clearer groups than the names used today? How often does a tumor's gene group differ from the name it was given at diagnosis? Can a computer program tell these groups apart from scanned pictures of the tissue?
Researchers will compare the groups found by the gene tests with the diagnoses given at the time. They will also look at how each group did over the years that followed. This shows which way of sorting tumors better matches what happened to participants.
Participants will not have extra visits, tests, or treatment for this study. The study does not change anyone's care.
Researchers will:
Use tumor tissue that was already taken as part of regular care Read the deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in the tumor, which carry its genetic instructions Read the chemical marks on the tumor's DNA that switch genes on and off Scan the glass slides of the tissue into digital pictures Collect facts about treatment and health from medical records
Participants who are newly diagnosed will also be asked for a blood sample. Blood shows which gene changes a person was born with and which ones started in the tumor.
If the study finds a gene change that matters for a participant's care, the study team tells the treating doctors through normal hospital routines.
Inclusion: Histopathologically diagnosed tumor or tumor-like lesion of bone or soft tissue, including benign, intermediate and malignant lesions; Tissue sampled, resected or reviewed at the study center; Archived diagnostic material available and adequate for the analyses of the relevant cohort: formalin-fixed paraffin-embedded tissue, fresh-frozen tissue, or diagnostic glass slides; For the prospective cohort, documented informed consent.
Exclusion: No retrievable diagnostic material or diagnostic report; Documented objection by the participant to the research use of their material or data.